Articles On Orthocell (ASX:OCC)

Australian regenerative medicine company Orthocell (ASX:OCC) says its 'Striate +' produce has been recommended to be added to the Australian government's Prostheses List.

Orthocell Ltd (ASX: OCC) shares are edging higher in mid-afternoon trade after the company announced it has been recommended for inclusion on the Australian Prosthesis List. At the time of writing, the Orthocell share price has risen 3.85%...

The Prosthesis list defines the minimum amount of benefit to be paid by private insurers for CelGro®product used in approved dental bone and soft tissue repair procedures.

CelGro represents a breakthrough in soft tissue reconstruction and offers commercial potential in existing addressable markets of bone, tendon, nerve and cartilage, and wider applications in general surgical and soft tissue reconstructive a...

Australian regenerative medicine company Orthocell (ASX:OCC) has announced the publication of a successful case study focused on the combination of its CelGro collagen medical device with autologous tenocyte implantation (Ortho-ATI)...

Perth-based regenerative medicines outfit Orthocell has developed a biological collage membrane device, called Celgro. And it has FDA approval. ... Read More The post Dr Boreham’s Crucible: Orthocell’s got some nerve… and FDA, TGA and CE ap...

The case study has proven that CelGro®, combined with Ortho-ATI® is effective in returning a patient to normal function and has been published in the International Journal of Case Reports.

Regenerative medicine company Orthocell (ASX:OCC) has announced it has received an R&D Tax Incentive refund of almost $2.4 million for 2019-20.

The funds will be invested into the Striate+ partnering program, progression of CelGro® nerve repair regulatory approvals, and to advance the development and commercialisation of Ortho-ATI®.

Drug development is a long and tedious process, often taking years to reach commercialisation. Small-cap biotech company Orthocell Ltd [ASX:OCC] knows this all too well, having spent years bringing their tissue repair... The post Orthocell...

Summary ASX 200 recovered after slipping in the early trade, with healthcare and technology sectors pulling the ASX chords. ASX rebound by driven by Pro Medicus (11.01per cent), Polynovo (5.2 per cent), Afterpay (7.46 per cent), and Zi...

The Orthocell Ltd (ASX: OCC) share price is one of the best performers on the market today. This comes after the company announced that it has received regulatory approval for its flagship product, CelGro. At the time of writing, the regen...

US market clearance provides a pathway for OCC to continue driving the development of CelGro collagen medical device in the key peripheral nerve repair application, and it will pursue negotiations with multi-national dental companies for ma...

US market clearance provides a pathway for OCC to continue driving the development of CelGro collagen medical device in the key peripheral nerve repair application, and it will pursue negotiations with multi-national dental companies for ma...

Summary Orthocell has received FDA 510(k) clearance to market and supply its CelGro device in the US market. It is an approved device which helps in the dental bone and tissue regeneration procedures. Managing Director of Orthocell, P...

The company recently received the green light to introduce its CelGro® collagen medical device into the Australian dental bone and tissue regeneration market.

Summary Regenerative medicine company Orthocell receives market approval for its collagen medical device, CelGro®. The Company is well-positioned to achieve approvals for production and supply of CelGro® for nerve and tendon repair. O...

The Orthocell Ltd (ASX: OCC) share price is surging higher today. This comes after the biotechnology company received Australian market approval for its CelGro product. CelGro is a collagen scaffold that supports tissue reconstruction and...

The approval positions Orthocell well for US Food and Drug Administration (FDA) approval, targeted for 2021. 

ASX-listed regenerative medicine player Orthocell Limited (ASX:OCC) announced a major achievement towards obtaining Therapeutic Goods Administration (TGA) approval for its collagen medical device, CelGro®. With the TGA providing conformity...

The Orthocell Ltd (ASX: OCC) share price is edging higher today. This comes after the company announced it has completed an important step to obtaining its commercial licence in Australia for its CelGro medical device. During market open,...

The company has successfully completed the Australian TGA Conformity Assessment process around the safety and performance of CelGro® in dental bone and tissue regeneration procedures.

Summary Regenerative medicine company Orthocell Limited released positive results in its CelGro® nerve repair study. The Company revealed that patient enrolment for the CelGro® nerve repair study is now complete. Following these positi...

The Orthocell Ltd (ASX: OCC) share price is 17% higher this morning, after the company released positive results in its CelGro nerve repair study. At the time of writing, Orthocell shares are trading at 44 cents per share. About Orthocell ...

Orthocell’s (ASX:OCC) latest clinical study results led to shares rising more than 20 per cent this morning. Orthocell’s CelGro technology involves ... Read More The post Orthocell shares spike after more positive clinical data from its ner...

The regenerative medicine company is now progressing regulatory applications in Australia and will start a US regulatory study shortly.

The paper ’Collagen Membrane for Guided Bone Regeneration in Dental and Orthopedic Applications’ reports positive results from pre-clinical and clinical study results for the CelGro treatment.

The paper ’Collagen Membrane for Guided Bone Regeneration in Dental and Orthopedic Applications’ reports positive results from pre-clinical and clinical study results for the CelGro treatment.

The company’s portfolio of regenerative medicine products have shown in clinical studies and real world evidence to return patients to work, activities of daily living and elite sport pain-free.

Regenerative medicine company Orthocell (ASX:OCC) has announced the publication of positive pre-clinical and clinical results for the use of its CelGro in enhancing repair of critical bone defects in the 'Tissue Engineering' Journal...

The SAS product use also provides real-world evidence for the safety and efficacy of CelGro®, further validating data collected in clinical trials.

The company is well-positioned to establish its CelGro® product as the best-in-class membrane for bone and soft tissue repair and to realise multiple commercial partnering opportunities.

The company’s commercialisation strategy for the product will leverage the TGA results for regulatory submission in the US.

The trademark will remain in force for an initial period of 10 years and may be renewed for successive periods of 10 years thereafter.

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week The life s...

The study captures patient feedback/outcomes for reduction of pain, functional improvement and overall satisfaction, in patients suffering from chronic tendon injuries

Australian regenerative medicine company Orthocell (ASX:OCC) has announced the completion of recruitment in the Ortho-ATI shoulder tendon study it is conducting in collaboration with DePuy Synthes Products, part of the Johnson &...

The companies will begin the trial to assess the effectiveness of Ortho-ATI, a novel cell therapy developed to treat chronic tendon injuries.

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week Clinical t...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week Clinical t...

Regenerative medicine company Orthocell (ASX:OCC) has announced the appointment of Leslie Wise, JD, as executive director.

With a leading regenerative medicine portfolio and experienced senior advisory team, Orthocell is well-positioned to drive its products into the US, EU and AU markets.

The therapy features in a chapter of the book which has been downloaded more than 3,000 times.

A 510(k) is a premarket submission made to FDA to demonstrate that the device to be marketed is as safe and effective.

PharmAust (ASX:PAA) shares surged this morning on news a clinical trial of its drug that fights cancer in dogs has so far been a success. The company released interim results showing the majority of dogs have responded well to the treatment...